CommercialCoverageHigh impact
State and School Employees' Health Insurance Plan - Intravenous Iron Replacement Therapy
Blue Cross & Blue Shield of Mississippi·MS · Hematology, Oncology, Nephrology +4 more·Medical Policy
Effective date
Jan 1, 2025
We identified it
Jun 20, 2026
Summary
Blue Cross Blue Shield of Mississippi has designated four specific intravenous iron replacement medications as not medically necessary, effective January 1, 2025. Claims for Feraheme, Ferrlecit, Injectafer, and Monoferric (including their administration services) will be denied as there are other formulary alternatives available.
Action Required
By January 1, 2025: Billing team must update system to flag HCPCS codes J1437 (ferric derisomaltose/Monoferric) and J1439 (ferric carboxymaltose/Injectafer) as non-covered for BCBS Mississippi State and School Employee plans. Providers must switch to formulary-approved IV iron alternatives. Review formulary for covered options before administering IV iron therapy. Claims for these medications and their administration will be denied.